INTRODUCTION
Prostate cancer is the second most frequently diagnosed cancer affecting male adults and the sixth most common cause of can cer associated death in men across the world (1). The major risk factors for prostate cancer are old age, race, inherited suscepti bility and environmental and behavioral factors such as diets (2, 3) . Treatment options of prostate cancer include active surveil lance, surgical resection, androgen ablation therapy, radiother apy, and cryotherapy variously depending on risk grouping, medi cal comorbidities and age at the diagnosis of the patients (46).
Prostate cancer is heterogeneous in terms of clinical behav iors, histological and molecular features, and treatment options (47). Although most patients with low and intermediaterisk prostate cancer follow an indolent clinical course and are po tentially curative by surgical resection or radiotherapy, patients with highrisk prostate cancer have higher rate of cancer related death and conventional chemotherapy and radiation therapy are of limited effectiveness for them (2, 46, 8) . Androgen depri vation therapy has good efficacy for advanced disease to lead to either a partial or complete remission initially. However most patients evolve towards an androgenindependent state within a few years and result in death due to widespread metastasis (6) . Therefore, more improved treatments and novel biomark ers are strongly needed in order to overcome metastasis and le thal recurrence for advanced prostate cancer as well as unpre dictable cases of low or intermediate risk groups.
Peroxisome proliferatoractivated receptors (PPARs) are a group of 50kDa liganddependent transcription factors local ized at human chromosome 3p25 and belong to a member of the nuclear hormone receptor superfamily such as steroid and thyroid hormones (911). They are composed of three isoforms (PPARα, PPARγ, and PPARδ/β) and require heterodimeriza tion with the retinoid X receptor for optimal DNA binding to spe cific response elements, termed to as peroxisome proliferator response elements (PPREs), in the promoter of the various tar get genes (911). The nuclear receptor superfamily was named because they show prominent nuclear localization. Among the subtypes, PPARγ is known to play a prominent role in adipocyte differentiation, the inflammatory response and peripheral glucose utilization (9, 11) . Recent studies have suggested that PPARγ play a key role in tumorigenesis as a tu mor suppressor and PPARγ agonists showed antiproliferative and proapoptotic actions in cancers (8, 12, 13) . Currently PPARγ agonists including the most active natural ligand, 15deoxyD12, 14prostaglandin J2 (15dPGJ2) and the most specific PPARγ synthetic agonists, the thiazolidinediones (TZDs) are used for enhancing insulin sensitivity in type II diabetes patients (9) . And they have been introduced in clinical trials for treatment of sever al malignancies such as colorectal and esophageal cancers (9, 14) .
ORIGINAL ARTICLE
Many in vivo or in vitro studies have shown antineoplastic effect of PPARγ ligands in prostate cancers (15, 16) . It has been reported that exposure to the TZDs has been shown to increase apoptotic activity in LNCaP, C42, and PC3 prostate cancer cells and a combination therapy using histone deacetylases in hibitors and PPARγ agonists decrease invasiveness of the pros tate adenocarcinoma cells in vivo (13, 15, 16) . Efatutazone is re cently introduced as a novel thirdgeneration TZD PPARγ ago nist, which is at least 500fold more potent than the other TZDs such as troglitazone and pioglitazone (17) . Therefore, PPARγ and its agonists have recently drawn more attention and prom ise in terms of chemoprevention and chemotherapy for cancer treatment and it has been also considered as a promising mo lecular target for anticancer targeted therapy development in prostate cancers (18) .
However, there is little or controversial information on PPARγ expression and clinical implications in the clinical specimen of prostate cancers (1820). Whereas Nakamura et al. (19) report ed PPARγ expression showed an inverse correlation with worse clinical parameters including pT stage and serum PSA levels, Rogenhofer et al. (20) reported PPARγ protein and mRNA ex pression were found to be significantly higher in advanced pros tate cancers than in localized cancer. Therefore, further studies are needed to obtain a better understanding of the clinical roles of PPARγ in human prostate cancers for considering a poten tial trial of PPARγ ligands therapy for the patients.
The aim of this study was to validate PPARγ expression in malignant and benign prostate tissues of a clinically wellcharac terized prostatectomy cohort by immunohistochemistry and quantitative realtime PCR in a Korean population. (21) .
MATERIALS AND METHODS

Case selection
Construction of tissue microarray
TMAs were constructed using a manual tissue arrayer (Beecher Instruments, Sun Prairie, WI, USA). Three randomly represen tative 0.6 mm cores were obtained from the most representative caner areas of formalinfixed paraffinembedded tissue blocks and were arranged in TMA blocks.
Immunohistochemistry
The representative paraffin blocks from 63 radical prostatectomy specimens and TMAs including 667 PCAs were sectioned into 4 μm slices, deparaffinized, and antigens demasked in EDTA buffer, pH 8.5 (Cell Conditioning 1 solution, Ventana). Immu nohistochemical analysis was conducted with the Ventana Dis covery XT automated staining system (Ventana Medical Sys tems, Tucson, AZ, USA) according to manufacturer's instruc tion. Staining of two PPARγ antibodies (C26H12, rabbit mono clonal, 1:400, Cell Signaling Technology, Danvers, MA, USA; H100, rabbit polyclonal, 1:25, Santa Cruz Biotechnology, Santa Cruz, CA, USA) was used according to each manufacturer's in struction. Detection of PPARγ was carried using the iVIEW DAB Detection Kit (Ventana). All staining reactions were carried out in Tris buffer, pH 7.47.8 (Ventana reaction buffer, Ventana). Fi nally, slides were counterstained with hematoxylin I, followed by bluing reagent (Ventana). Omitting of primary antibody was used for the negative control and urothelial carcinoma in blad der and thyroidal follicular carcinoma were used for the posi tive control.
RNA extraction
The H&E slides from all samples were reviewed by two patholo gists to mark the areas with the collected sections of 63 prostatec tomy specimens composed of 10 PCAs with low Gleason score (≤ 7, Low GS), 10 PCAs with high Gleason score ( > 7, High GS), five benign prostate tissues as a control for fold change, and thy roidal follicular carcinoma showing PPARγ nuclear staining confirmed by immunohistochemistry as positive control. Sub sequently, 10 μm thick sections cut from the formalinfixed, par affinembedded blocks for dissecting the target area from the slides, then, transferred into microcentrifuge tubes. Before RNA isolations, deparaffinization was performed with 1 mL xylene with 10 min incubation time, and 1 mL absolute ethanol for 10 min. Total RNA was extracted by using High Pure FFPE RNA Isolation Kit (Roche Applied Science, Penzberg, Germany), ac cording to the manufacturers' instructions. RNA yield and qual ity was assessed by measuring the ratio of spectrophotometric absorbance (260 nm/230 nm and 260 nm/280 nm) using Nano Drop ® ND1000 Spectrophotometer (Thermo Fisher Scientific Inc., Waltham, MA, USA). The extracted RNA samples were con sidered to be acceptable only with absorbance ratio between 1.0 and 2.0 at 260 nm/230 nm, and between 1.8 and 2.0 at 260 nm/280 nm.
Quantitative real-time polymerase chain reaction
Complimentary DNA was synthesized by reverse transcription using Transcriptor First Strand cDNA Synthesis Kit (Roche Di agnostics, Mannheim, Germany). 1 μg of total RNA were reverse transcribed with a combination of anchoredoligo (dT) and ran dom hexamer primers, according to the manufacturers' instruc tions. To assess PPARγ (Hs01115513) and GAPDH (Hs99999905) gene expression, we used predesigned quantitative realtime TagMan Gene Expression Assays (Applied Biosystems, Foster city, CA, USA). Quantitative realtime PCR reactions were per formed in final volume of 20 μL using 10 ng cDNA/well and 10 μL FastStart Essential DNA Probes Master (Roche Diagnostics) according to the manufacturers' instructions. Thermal cycling conditions on the LightCycler Nano System were the following: Enzyme activation: 95°C for 10 min, 45 cycles of amplification: 95°C for 10 sec, 60°C for 30 sec. Each quantitative realtime PCR analysis was performed in triplicate. The glyceraldehyde3phos phate dehydrogenase (GAPDH) was used as the internal con trol gene. The normalized amount of each target mRNA present in 20 PCAs cases was calculated by benign prostate tissue cases.
Statistical analyses
The unpaired ttest, chisquare test or LinearbyLinear Associ ation test were used to compare the PPARγ immunoreactivity in accordance with the clinicopathologic variables including age, pT stage and Gleason score. The unpaired ttest was also used to compare the relative mRNA expression level between groups and controls. P < 0.05 was considered significant. All statistical analyses were conducted using SPSS v. 17.0 (SPSS, Inc., Chicago, IL, USA).
Ethics statement
This study was approved by the institutional review boards (IRB) of Konkuk University Medical Center (KUH1210030). Informed consents were waived by the IRB.
RESULTS
The clinicopathologic features of the PCAs from 730 patients including age, Gleason score and pathologic T stage enrolled in this study are summarized in Table 1 Fig. 1B) and 15.9% of PCAs (10/63) from the whole sec tions (Fig. 2AC) (Table 1 ). Tumor heterogeneity of PPARγ im munoreactivity was identified in PCAs (Fig. 2D) .
Most benign prostatic glands showed negative immunoreac tivity of PPARγ except for variable weak cytoplasmic staining of basal cells in some glandular epithelum (Fig. 3A) . Verumonta num mucosal epithelium showed nuclear staining of PPARγ (Fig. 3B) and some glandular epithelium of benign prostatic hyperplasia revealed nuclear and/or cytoplasmic immunore activity of PPARγ (Fig. 3C and D) .
Positive controls revealed nuclear immunoreactivity of PPARγ in thyroid follicular carcinoma, urothelial carcinoma of bladder and periprostatic adipocytes (Fig. 4AC) . No association between PPARγ cytoplasmic expression and clinicopathologic parame ters including age, Gleason score and pathologic stage was not ed ( Table 2) . The expression level of PPARγ mRNA for each sample was standardized based on the mean expression level of five benign prostate tissues as a control for fold change. The mean fold change indicated that the constitutive PPARγ mRNA in PCAs (mean fold change = 0.68) was marginally detectable compared to that of thyroid follicular carcinoma as a positive control (mean fold (Fig. 5A ). The expression of PPARγ mRNA were downregulated in low GS (mean fold change 0.67, P = 0.007) and high GS (mean fold change 0.66, P = 0.022) groups when compared to that of the benign prostate tissues (Fig. 5A ). 10% of low GS (1/10) and 33.3% of high GSs (3/10) showed higher expression of PPARγ mRNA compared to that of the be nign prostate tissues (Fig. 5B ). There were no significant differ ence of mRNA expression of PPARγ between the low GS and high GS groups (P = 0.905) (Fig. 5B) . There is no significant dif ference of mRNA expression between cytoplasmic immunopos itive PCAs and immunonegative PCAs of PPARγ (P = 0.88).
DISCUSSION
PPARγ expression has been investigated in various human dis eases including cancers, diabetes, atherosclerosis, and neuro degenerative disease (9, 11, 22) . The PPARγ gene is known to function as a tumor suppressor gene involved in tumor growth inhibition, apoptosis and tumor cell differentiation (9, 15, 17) . It has been mapped to chromosome 3p25, of which frequent het erozygous deletions are observed in human cancers including prostate cancer (9) . Its expression level is known to be varied dependent on different types of tissues and carcinomas (23) . This receptor has initially shown nuclear localization of genom ic activity via direct or indirect transcription as a key regulator of metabolic homeostasis and inflammatory response (10, 11, 18) . Recently the nongenomic activity and the cytoplasmic lo calization of the receptor have been also magnified as new chal lenging from a functional perspective in the diseases (10, 24, 25) .
Our results revealed that PPARγ was marginally detectable in prostate tissues of Korean population and the localization of the receptor was mainly in the cytoplasm, not in the nucleus. We first planned this study under the hypothesis that PPARγ would be expressed in the nuclei of tumor cells as reported in previous studies that showed its nuclear immunoreactivity in over 70% of prostate cancer (19, 20) . These conflicting findings prompted us to discuss several questions from all angles inclu ding extranuclear localization of PPARγ, ethnical variability and technical issues of immunohistochemistry.
PPARγ is known to exert pleiotropic effects in glucose and lipid metabolism, antiinflammatory responses, apoptosis and carcinogenesis by modulating specific gene expression (9, 11, 26) . A number of studies have described that the PPARγ local ize predominantly in the nucleus to exert its genomic effect via direct or indirect enhancement or inhibition of transcription (9, 11, 26) . However, recently new convincing evidences of the non http://dx.doi.org/10.3346/jkms.2015.30.5.533 genomic activity of the PPARγ and their cytoplasmic localiza tion have been reported in many studies (10, 16, 18, 24, 25) . Bur germeister and Seger described that PPARγ has cytoplasmic activities that are caused by mitogenic stimulation suppressing PPARγ's genomic activity and MEKdependent shuttle may also play a role in the control of the extranuclear/nongenomic actions of PPARγ (25) . In this study, the cytoplasmic localiza tion of PPARγ would be also noticeble to support extranucle ar/nongenomic actions of the PPARγ.
Recently, Lee et al. demonstrated PPARγ was localized pre dominantly in the perinuclear region and cytoplasm in the un treated prostate PC3 and LNCap cells and 4Omethylhonoki ol (MH), a constituent of Magnolia officinalis increased the pro tein and transcriptional expressions of PPARγ via its nuclear translocation from the cytoplasmic location in those cells (16) .
As most previous studies has demonstrated mainly quantitative or qualitative analysis of PPARγ, Lee et al. 's study showing re markable morphologic localization of PPARγ protein in prostate cancer cell lines is noteworthy. It corresponded with its cytoplas mic location in clinical specimen with prostate cancer in the current study. It is also very interesting to draw a hypothetical reasoning that PPARγ can play a significant and different role as a nuclear transcription factor in in vivo human prostate can cers when it is induced from cytoplasm to nuclei by its agonists.
Although many studies have indicated beneficial effects with PPARγ ligand treatment, the role of PPARγ in cancer therapy is still controversial showing either protumorigenic or antineo plastic effects in studies (12, 13, 27) . Nonetheless, many previ ous studies have shown that TZDs decrease the growth rate of the human prostate cancer cells both in vitro and in vivo (13, 28) . And two clinical trials using the TZD troglitazone showed effective therapeutic results in the patients with prostate cancer (9, 29) . Recently Sawayama et al. demonstrated efatutazone, a novel thirdgeneration TZD PPARγ agonist which is at least 500fold more potent than troglitazone alone or in combination with cetuximab may offer as a potential therapy for esophageal squamous cell carcinomas (17) . They also demonstrated efat utazone combined with cetuximab showed synergistic antipro liferative effects by suppressing both the PI3KAkt and MAPK pathways. Therefore, it will be important in the further experi ment with these promising TZD drugs which may improve the prostate cancer prognosis.
Our study demonstrated PPARγ protein and mRNA expres sion are low in nonneoplastic and neoplastic prostate tissues of Korean population, and PPARγ mRNA expression was observ ed to be slightly lower in prostate cancers than in the benign prostatic glands. These results were supported by several arti cles that PPARγ mRNA expression in carcinomas was lower than that in normal prostatic tissues (12, 23) . However, the up regulation of PPARγ expression is a frequent occurrence in a variety of different malignant tumors (30, 31) . Segawa et al. re ported high expression level of PPARγ mRNA in prostatic in traepithelial neoplasia (PIN) and prostatic carcinoma com pared to low expression level of PPARγ mRNA in benign pros tatic hyperplasia, and no expression of PPARγ in normal pros tatic tissue (32) . Our study has some limitations because of small sample size, fixed tissue for RTPCR and lack of in situ hy bridization. On the other hand, as PPARγ activity is known to be modulated directly and indirectly particularly at its tran scriptional activity regulated by posttranslational modifica tions (10, 25) , further research will be necessary to clarify these controversial findings.
These controversies in PPARγ expression could be elucidat ed that the pathogenesis of prostate cancer reflecting both he reditary and environmental components is ethnically different (7, 26) . The genetic changes as well as the incidence and prog nosis of prostate cancer have shown strong ethnic variance, par ticularly in Asian populations (7) . For example the frequency of transcription regulator ERG gene is much lower in Asian coun tries in contrast to higher ERG frequency in Western countries (33, 34) . As a possible association between PPARγ polymor phism and the risk of developing cancer has been reported (26, 35) , polymorphisms in the PPARγ gene that show increased or decreased function variants may cause the different expression and role of PPARγ in prostate cancers of Korean men. Epide miological studies have shown certain environmental elements such as the consumption of red meat and animal fats have had an effect on the increased rate of prostate cancer (3). In Korea, prostate cancer is the fifth most frequently diagnosed cancer in males and has been rapidly increased according to transition to Western dietary habits among Korean (36) . These perspectives may implicate a link between PPARγ's function involved in lip id metabolism and its role in prostatic carcinogenesis.
On the other hand, in recent oncologic research and medi cine, accuracy of immunohistochemistry to validate the target genes is very important step to move to the further effective tar get therapy (37) . We used three appropriate positive controls for PPARγ immunostaining, which demonstrated the positive nuclear immunoreactivity well in urothelial carcinoma and fol licular carcinoma as well as in periprostatic adipocytes as the internal control. We also tested primary antibody using two dif ferent PPARγ antibodies that are widely used in the literatures, which confirmed the same results by both antibodies at two dif ferent hospital laboratories. The previous literature have describ ed both nuclear and cytoplasmic immunoreactivity of PPARγ, but revealed much nonspecific background staining of PPARγ immunoreactivity in the given photos (18, 19) with no positive or negative control information. Commercially available and well characterized PPARγ antibodies have been recently intro duced to clinical and research communities, therefore, further study is needed to investigate the expression pattern of PPARγ using an optimized immunohistochemistry in a large cohort of http://dx.doi.org/10.3346/jkms.2015. 30.5.533 clinical specimens with prostate cancers.
In conclusion, our study demonstrated the cytoplasmic lo calization of PPARγ protein expression supporting its nonge nomic cytoplasmic activity in carcinogenesis of prostate cancer. Further investigations are necessary to clarify clinical or biolog ical roles of PPARγ and to provide useful information of PPARγ agonists for a new therapeutic option in the patients with pros tate cancers.
